Canaccord analyst Gary Newman reiterated a Buy rating and $300.00 price target on Jazz Pharmaceuticals (NASDAQ: JAZZ).The analyst commented: "JAZZ ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments